Elicio Therapeutics (ELTX) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing immunotherapies for cancer patients with limited treatment options, leveraging proprietary Amphiphile (AMP) technology to generate robust anti-tumor T cell responses by targeting lymph nodes.

• Lead program ELI-002 7P targets seven KRAS mutations in pancreatic ductal adenocarcinoma (PDAC), covering 88% of PDAC patients and 25% of all solid tumors; currently in Phase 2 clinical trials with anticipated final analysis in H1 2026.

• Pipeline includes additional preclinical candidates targeting other oncogenic mutations (b-raf, p53) and aims to provide off-the-shelf therapeutic options, avoiding delays and costs of personalized therapies.

• Company formed through a merger in 2023 and operates from Boston, Massachusetts.

Financial performance and metrics

• Audited financial statements for the year ended December 31, 2024, are incorporated by reference, with an explanatory paragraph regarding the company's ability to continue as a going concern.

• As an emerging growth and smaller reporting company, presents only two years of audited financials and reduced executive compensation disclosures.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital, research and development, business expansion, strategic transactions, and general corporate purposes; specifics to be detailed in future prospectus supplements.

• Pending use, proceeds may be invested in investment-grade, interest-bearing securities.